Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

The FDA, which was supposed to decide by April 1 whether it would approve Novavax's application for a full license, is seeking more clinical studies of the vaccine. Now, because other drugmakers ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the FDA means a product can stay on the market even after a health emergency ...

Shares in food delivery giant Deliveroo surged by 17% at the start of trading in London on Monday, following news that US-based rival DoorDash (DASH) had made a takeover approach. The bid, disclosed ...

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...

Brinker, the owner of Chili's, has seen shares soar 20% so far in 2025. The earnings report on Tuesday could take them a leg up or down. The additional step, which could cost millions of dollars, goes ...

Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...